JP2017510631A5 - - Google Patents

Download PDF

Info

Publication number
JP2017510631A5
JP2017510631A5 JP2016575643A JP2016575643A JP2017510631A5 JP 2017510631 A5 JP2017510631 A5 JP 2017510631A5 JP 2016575643 A JP2016575643 A JP 2016575643A JP 2016575643 A JP2016575643 A JP 2016575643A JP 2017510631 A5 JP2017510631 A5 JP 2017510631A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016575643A
Other versions
JP2017510631A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/020694 external-priority patent/WO2015139020A2/en
Publication of JP2017510631A publication Critical patent/JP2017510631A/ja
Publication of JP2017510631A5 publication Critical patent/JP2017510631A5/ja
Pending legal-status Critical Current

Links

JP2016575643A 2014-03-14 2015-03-16 癌に対しｎｋｇ２ｄ経路機能を回復させるためのワクチン組成物および方法 Pending JP2017510631A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461953064P 2014-03-14 2014-03-14
US61/953,064 2014-03-14
PCT/US2015/020694 WO2015139020A2 (en) 2014-03-14 2015-03-16 Vaccine compositions and methods for restoring nkg2d pathway function against cancers

Publications (2)

Publication Number Publication Date
JP2017510631A JP2017510631A (ja) 2017-04-13
JP2017510631A5 true JP2017510631A5 (ja) 2017-07-06

Family

ID=54072606

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016575643A Pending JP2017510631A (ja) 2014-03-14 2015-03-16 癌に対しｎｋｇ２ｄ経路機能を回復させるためのワクチン組成物および方法

Country Status (7)

Country Link
US (1) US10279021B2 (ja)
EP (2) EP3116903A2 (ja)
JP (1) JP2017510631A (ja)
CN (2) CN106456728A (ja)
AU (3) AU2015229009B2 (ja)
CA (2) CA3124243A1 (ja)
WO (1) WO2015139020A2 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ721184A (en) 2011-09-30 2018-08-31 Dana Farber Cancer Inst Inc Therapeutic peptides
EP2970908B1 (en) 2013-03-15 2019-12-25 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
JP6450381B2 (ja) 2013-07-05 2019-01-09 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション がんを処置するための可溶性ｍｉｃ中和モノクローナル抗体
BR112018010705A8 (pt) * 2015-12-04 2019-02-26 Dana Farber Cancer Inst Inc vacinação com o domínio mica/b alfa 3 para o tratamento de câncer

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP0351410A1 (en) 1987-03-18 1990-01-24 3i RESEARCH EXPLOITATION LIMITED Complement-binding peptide
GB8709290D0 (en) 1987-04-16 1987-05-20 Secretary Trade Ind Brit Precision motion slideways
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
ES2202310T3 (es) 1991-12-13 2004-04-01 Xoma Corporation Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
AUPN568095A0 (en) * 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998019167A2 (en) 1996-10-29 1998-05-07 Fred Hutchinson Cancer Research Center, Inc. Cell stress regulated human mhc class i gene
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5830698A (en) 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
US20090175821A1 (en) 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
EP1252192B1 (en) 2000-02-11 2006-08-16 MERCK PATENT GmbH Enhancing the circulating half-life of antibody-based fusion proteins
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20040115198A1 (en) 2001-02-28 2004-06-17 Fred Hutchinson Cancer Research Center Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
WO2002068615A2 (en) 2001-02-28 2002-09-06 Fred Hutchinson Cancer Research Center, Inc. Activation of lymphocyte populations expressing nkg2d using anti-nkg2d antibodies and ligand derivatives
US6566208B2 (en) 2001-07-25 2003-05-20 Chartered Semiconductor Manufacturing Ltd. Method to form elevated source/drain using poly spacer
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2003089616A2 (en) 2002-04-22 2003-10-30 Fred Hutchinson Cancer Research Center Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
ATE394674T1 (de) 2002-04-22 2008-05-15 Univ Florida Funktionalisierte nanopartikel und verwendungsverfahren
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
DK2345671T3 (en) 2002-09-27 2016-02-15 Xencor Inc Optimized Fc variants and methods for their formation
AU2003286467B2 (en) 2002-10-15 2009-10-01 Abbvie Biotherapeutics Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
CA2519953C (en) * 2003-03-24 2016-01-05 The Scripps Research Institute Dna vaccine against tumor growth and methods of use thereof
US7666417B2 (en) 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
AU2004259398A1 (en) 2003-06-27 2005-02-03 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
US20080089892A1 (en) 2004-01-12 2008-04-17 Eli Lilly And Co. Fc Region Variants
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
DK1776384T3 (da) 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT-Fc-REGIONER
CA2584859C (en) 2004-10-25 2017-11-07 Merck & Co., Inc. Anti-addl antibodies and uses thereof
US20080148432A1 (en) 2005-12-21 2008-06-19 Mark Scott Abad Transgenic plants with enhanced agronomic traits
EP2284194A1 (en) 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
US8110196B2 (en) 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
SI1907000T2 (sl) 2005-06-08 2020-07-31 Dana-Farber Cancer Institute Postopki in sestavki za zdravljenje persistentne HIV infekcije z inhibicijo programiranih celični smrtnih 1 (PD-1) poti
JP2009514528A (ja) 2005-11-03 2009-04-09 フレッド ハッチンソン キャンサー リサーチ センター Ｎｋｇ２ｄ陽性ｃｄ４＋細胞による免疫応答の負の免疫調節法
DE102006009847A1 (de) 2006-03-01 2007-09-06 Sweredjuk, Robert, Dr. Verfahren von Absorbieren von Schadstoffen und Gerüchen
WO2008036981A1 (en) 2006-09-22 2008-03-27 Dana-Farber Cancer Research, Inc. Methods for treating mica-related disorders
CA2664567C (en) 2006-10-04 2016-04-26 Dana-Farber Cancer Institute, Inc. Tumor immunity
EP2150565A2 (en) 2007-04-23 2010-02-10 Fred Hutchinson Cancer Research Center NEGATIVE IMMUNOMODULATION OF IMMUNE RESPONSES BY ERp5
NZ581395A (en) 2007-05-14 2012-08-31 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
WO2011063336A2 (en) 2009-11-20 2011-05-26 President And Fellows Of Harvard College Secondary site of antigen stimulation for therapeutic vaccination
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
JP5690143B2 (ja) 2008-02-13 2015-03-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 持続的細胞プログラミング装置
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8182809B1 (en) 2008-09-08 2012-05-22 University Of Washington Methods for treating cancer by inhibiting MIC shedding
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
US8207497B2 (en) 2009-05-08 2012-06-26 Ionsense, Inc. Sampling of confined spaces
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
KR101688522B1 (ko) 2009-12-15 2016-12-21 삼성전자주식회사 안지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도
US8796420B2 (en) * 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
US8753640B2 (en) 2011-05-31 2014-06-17 University Of Washington Through Its Center For Commercialization MIC-binding antibodies and methods of use thereof
CN102911270A (zh) 2011-08-05 2013-02-06 浙江大学 一种抑制移植器官慢性排斥反应的抗体的制备及纯化方法
NZ721184A (en) 2011-09-30 2018-08-31 Dana Farber Cancer Inst Inc Therapeutic peptides
US10577416B2 (en) 2012-02-07 2020-03-03 Innate Pharma, S.A. Mica binding agents
EP2970908B1 (en) 2013-03-15 2019-12-25 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
ES2755129T3 (es) 2013-12-06 2020-04-21 Dana Farber Cancer Inst Inc Péptidos terapéuticos
EP3145953A1 (en) 2014-05-21 2017-03-29 Dana-Farber Cancer Institute, Inc. Methods for treating cancer with anti bip or anti mica antibodies

Similar Documents

Publication Publication Date Title
JP2017510631A5 (ja)
BE2015C047I2 (ja)
BR0000126B1 (ja)
BR0000695B1 (ja)
BR0000763F1 (ja)
BR0001536B1 (ja)
BR0001684B1 (ja)
BR0001810B1 (ja)
BR0002033B1 (ja)
BR0002402B1 (ja)
BR0002435B1 (ja)
BR0002694B1 (ja)
BR0002802B1 (ja)
BR0002874B1 (ja)
BR0003166B1 (ja)
BR0003189B1 (ja)
BR0003208B1 (ja)
BR0003401B1 (ja)
BR0003686B1 (ja)
BR0003746B1 (ja)
BR0003751B1 (ja)
BR0003928B1 (ja)
BR0004687B1 (ja)
BR0005041B1 (ja)
BR0005085B1 (ja)